MedPath

Tagged News

Algorae Pharmaceuticals Partners with Peter MacCallum Cancer Centre to Validate AI-Predicted Drug Combinations

AIDrug DiscoveryOncology
  • Algorae Pharmaceuticals has partnered with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre to validate AI-predicted drug synergies using high-throughput screening technology.
  • The collaboration will test 24 drug candidates, including 21 AI-generated compounds, across four cancer cell lines: glioblastoma, pancreatic ductal adenocarcinoma, invasive breast carcinoma, and prostate carcinoma.
  • Full dataset from the screening program is expected within six months, with successful validation potentially accelerating regulatory pathways and creating opportunities for pharmaceutical partnerships.

Flagship Pioneering Appoints Biotech Veteran Rahul Kakkar as CEO of Somatic Genomics Company Quotient Therapeutics

Drug Discovery
  • Flagship Pioneering has appointed Rahul Kakkar, M.D., as CEO-Partner and CEO of Quotient Therapeutics, a company pioneering somatic genomics for drug discovery.
  • Dr. Kakkar brings nearly 20 years of biotech experience, including leadership roles at companies acquired for billions, such as Pandion Therapeutics (acquired by Merck for $1.85 billion) and Corvidia Therapeutics (acquired by Novo Nordisk for $2.1 billion).
  • Quotient has developed the world's first industrial platform for discovering novel drug targets through somatic genomics and has established collaboration agreements with Pfizer in cardiovascular and renal diseases.
  • The leadership transition comes as Quotient advances its pipeline and platform technology, with co-founder Jake Rubens transitioning to a board director role after successfully establishing the company's research operations.

X-Chem and Orion Pharma Expand Collaboration to Accelerate Small Molecule Drug Discovery

Drug DiscoveryAIOncology
  • X-Chem and Orion Pharma have expanded their strategic collaboration from hit identification to candidate selection, leveraging DNA-encoded library technology and AI-driven approaches for multiple early-stage programs.
  • The new Technology Access Agreement enables Orion to utilize X-Chem's integrated discovery capabilities, including DEL screening, AI-driven hit triage, and medicinal chemistry support to advance small molecule discovery.
  • This partnership combines X-Chem's ArtemisAI platform with computational and medicinal chemistry expertise to help partners make informed decisions earlier in the discovery process, reducing risk and improving outcomes.

Sapient Launches DynamiQ: Next-Generation Multi-Omics Platform Set to Transform Drug Discovery and Development

Precision MedicineDrug DiscoveryAI
  • Sapient has launched DynamiQ Insights Engine, an advanced multi-omics and real-world data platform that integrates thousands of protein, metabolite, lipid, and cytokine measures with matched genomic and clinical data.
  • The platform contains data from over 56,000 samples collected across multiple timepoints from diverse individuals, making it one of the most deeply phenotyped longitudinal datasets available for biomarker discovery and drug development.
  • DynamiQ's ability to track molecular changes over time alongside clinical outcomes enables researchers to better understand disease subtypes, predict treatment responses, and identify patients most likely to benefit from specific therapies.

CN Bio and Pharmaron Partner to Advance Organ-on-a-Chip Technology for Drug Development

Drug DiscoveryMonoclonal Antibody
  • CN Bio has formed a strategic partnership with Pharmaron to validate and integrate its PhysioMimix organ-on-a-chip technology across drug discovery applications, reducing reliance on animal testing.
  • The collaboration will initially focus on disease modeling, toxicity testing, and ADME studies, with plans to expand into novel applications addressing unmet needs in pharmaceutical R&D.
  • This partnership aligns with recent FDA announcements to phase out animal testing requirements for monoclonal antibodies, as the global organ-on-a-chip market is projected to reach $388 million by 2028.

Archetype Therapeutics to Present AI-Discovered Lung Cancer Drug Candidates at AACR 2025

AIDrug Discovery
  • Archetype Therapeutics will present in vivo proof-of-concept data for AI-identified small molecules targeting early-stage lung adenocarcinoma at the 2025 AACR Annual Meeting.
  • The company's generative AI platform identified novel and repurposed molecules that substantially outperform previously published compounds in preventing lung cancer invasion and metastasis.
  • Archetype is partnering with Abzena and Alloy Therapeutics to develop antibody-drug conjugates using clinical-stage and approved targeted therapy molecules discovered by their platform.
  • The Archetype platform enables virtual screening of billions of potential drugs per day in genomically-defined patient cohorts, advancing from AI-driven research to compelling in vivo data in just months.

Bayer Partners with ConcertAI to Accelerate Precision Oncology Drug Development Using AI

AIOncologyDrug Discovery
  • Bayer and ConcertAI have entered a multi-year strategic agreement leveraging AI and machine learning to accelerate clinical development in precision oncology.
  • The partnership utilizes ConcertAI's Translational360™ platform, which integrates data from over 9 million cancer patient records across the U.S., combining clinical, genomic, and imaging information.
  • This collaboration aims to enhance drug discovery by using multi-modal data and AI to better predict treatment responses, potentially delivering precision oncology treatments to patients faster.

Kyowa Hakko Kirin Partners with InveniAI to Accelerate Drug Repurposing Using AI Technology

OncologyAIDrug Discovery
  • Kyowa Hakko Kirin has signed a partnership with AI company InveniAI to use their AlphaMeld technology for discovering new therapeutic applications for existing pipeline drugs.
  • The collaboration focuses on maximizing R&D value in oncology, nephrology, and immunology by identifying alternate uses for drugs including mogamulizumab, istradefylline, and entinostat.
  • This partnership represents part of a growing trend where pharmaceutical companies are leveraging AI platforms to reduce development costs and accelerate time to market for drug candidates.

FDA Announces Shift from Animal Testing to AI Models, Boosting Recursion Pharmaceuticals Stock 20%

AIDrug DiscoveryMonoclonal Antibody
  • The FDA announced plans to replace animal testing with AI models and other human-relevant methods for drug development, initially focusing on monoclonal antibodies before expanding to other drug types.
  • Recursion Pharmaceuticals stock surged approximately 20% following the FDA announcement, as the company operates one of the largest biopharmaceutical datasets with over 60 petabytes of data for AI-driven drug discovery.
  • The regulatory shift could increase interest from other drugmakers in partnering with Recursion, which already collaborates with four major pharmaceutical companies including Bayer, Merck KGaA, Genentech, and Sanofi.

AI and Data Collaboration: Key to Advancing Cell Therapy in Biopharma Industry

AIDrug Discovery
  • Cellular Origins CEO Edwin Stone highlights the challenge of proprietary data silos hindering AI and machine learning implementation in biopharma despite their potential to advance patient care.
  • The biopharma industry faces a critical decision between competitive isolation and collaborative data sharing that could accelerate breakthroughs in cell therapy development.
  • AI and machine learning technologies are making significant impacts on drug discovery, particularly in virtual and software environments where they've found their initial applications.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.